250 related articles for article (PubMed ID: 25482741)
1. Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014.
Fleming S; Yannakou CK; Haeusler GM; Clark J; Grigg A; Heath CH; Bajel A; van Hal SJ; Chen SC; Milliken ST; Morrissey CO; Tam CS; Szer J; Weinkove R; Slavin MA
Intern Med J; 2014 Dec; 44(12b):1283-97. PubMed ID: 25482741
[TBL] [Abstract][Full Text] [Related]
2. Survey of antifungal prophylaxis and fungal diagnostic tests employed in malignant haematology and haemopoietic stem cell transplantation (HSCT) in Australia and New Zealand.
van Hal SJ; Gilroy NM; Morrissey CO; Worth LJ; Szer J; Tam CS; Chen SC; Thursky KA; Slavin MA
Intern Med J; 2014 Dec; 44(12b):1277-82. PubMed ID: 25482740
[TBL] [Abstract][Full Text] [Related]
3. Consensus guidelines for the use of empiric and diagnostic-driven antifungal treatment strategies in haematological malignancy, 2014.
Morrissey CO; Gilroy NM; Macesic N; Walker P; Ananda-Rajah M; May M; Heath CH; Grigg A; Bardy PG; Kwan J; Kirsa SW; Slavin M; Gottlieb T; Chen S
Intern Med J; 2014 Dec; 44(12b):1298-314. PubMed ID: 25482742
[TBL] [Abstract][Full Text] [Related]
4. Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haemopoietic stem cell transplantation, 2014.
Blyth CC; Gilroy NM; Guy SD; Chambers ST; Cheong EY; Gottlieb T; McGuinness SL; Thursky KA
Intern Med J; 2014 Dec; 44(12b):1333-49. PubMed ID: 25482744
[TBL] [Abstract][Full Text] [Related]
5. [Prophylaxis of fungal infections in haematological patients: pro].
Glass B
Dtsch Med Wochenschr; 2010 Sep; 135(38):1870. PubMed ID: 20842607
[No Abstract] [Full Text] [Related]
6. Preventing invasive fungal disease in patients with haematological malignancies and the recipients of haematopoietic stem cell transplantation: practical aspects.
Akan H; Antia VP; Kouba M; Sinkó J; Tănase AD; Vrhovac R; Herbrecht R
J Antimicrob Chemother; 2013 Nov; 68 Suppl 3():iii5-16. PubMed ID: 24155144
[TBL] [Abstract][Full Text] [Related]
7. Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2021.
Teh BW; Yeoh DK; Haeusler GM; Yannakou CK; Fleming S; Lindsay J; Slavin MA;
Intern Med J; 2021 Nov; 51 Suppl 7():67-88. PubMed ID: 34937140
[TBL] [Abstract][Full Text] [Related]
8. Primary Fungal Prophylaxis in Hematological Malignancy: a Network Meta-Analysis of Randomized Controlled Trials.
Lee CH; Lin C; Ho CL; Lin JC
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866872
[TBL] [Abstract][Full Text] [Related]
9. Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis.
Ziakas PD; Kourbeti IS; Mylonakis E
Clin Ther; 2014 Feb; 36(2):292-306.e1. PubMed ID: 24439393
[TBL] [Abstract][Full Text] [Related]
10. Antifungal prophylaxis during treatment for haematological malignancies: are we there yet?
Rogers TR; Slavin MA; Donnelly JP
Br J Haematol; 2011 Jun; 153(6):681-97. PubMed ID: 21504422
[TBL] [Abstract][Full Text] [Related]
11. Antifungal prophylaxis in hematopoietic stem cell transplant recipients.
Marr KA
Oncology (Williston Park); 2001 Nov; 15(11 Suppl 9):15-9. PubMed ID: 11757846
[TBL] [Abstract][Full Text] [Related]
12. Antifungal chemoprophylaxis in children and adolescents with haematological malignancies and following allogeneic haematopoietic stem cell transplantation: review of the literature and options for clinical practice.
Tragiannidis A; Dokos C; Lehrnbecher T; Groll AH
Drugs; 2012 Mar; 72(5):685-704. PubMed ID: 22413762
[TBL] [Abstract][Full Text] [Related]
13. [Fungal infections in children with malignant disease].
Michel G
Arch Pediatr; 2011 May; 18 Suppl 1():S3-7. PubMed ID: 21596284
[TBL] [Abstract][Full Text] [Related]
14. Current approaches in antifungal prophylaxis in high risk hematologic malignancy and hematopoietic stem cell transplant patients.
Wirk B; Wingard JR
Mycopathologia; 2009 Dec; 168(6):299-311. PubMed ID: 19247798
[TBL] [Abstract][Full Text] [Related]
15. Pharmacist review of high-risk haematology outpatients to improve appropriateness of antifungal prophylaxis.
Reslan Z; Lindsay J; Kerridge I; Gellatly R
Int J Clin Pharm; 2020 Dec; 42(6):1412-1418. PubMed ID: 33009604
[TBL] [Abstract][Full Text] [Related]
16. Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014.
Chau MM; Kong DC; van Hal SJ; Urbancic K; Trubiano JA; Cassumbhoy M; Wilkes J; Cooper CM; Roberts JA; Marriott DJ; Worth LJ
Intern Med J; 2014 Dec; 44(12b):1364-88. PubMed ID: 25482746
[TBL] [Abstract][Full Text] [Related]
17. Approaches to the management of invasive fungal infections in hematologic malignancy and hematopoietic cell transplantation.
Michallet M; Ito JI
J Clin Oncol; 2009 Jul; 27(20):3398-409. PubMed ID: 19487382
[TBL] [Abstract][Full Text] [Related]
18. [Prophylaxis of fungal infections in haematological patients: contra].
Schwartz S
Dtsch Med Wochenschr; 2010 Sep; 135(38):1871. PubMed ID: 20842608
[No Abstract] [Full Text] [Related]
19. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America.
Rex JH; Walsh TJ; Sobel JD; Filler SG; Pappas PG; Dismukes WE; Edwards JE
Clin Infect Dis; 2000 Apr; 30(4):662-78. PubMed ID: 10770728
[TBL] [Abstract][Full Text] [Related]
20. The role of primary antifungal prophylaxis in patients with haematological malignancies.
Pagano L; Caira M
Clin Microbiol Infect; 2014 Jun; 20 Suppl 6():19-26. PubMed ID: 24372659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
